Since Sarah Cohen was diagnosed with a rare form of cancer six years ago, she often has been given little chance of survival by doctors. They underestimated her spirit and determination. Sarah defied the odds to collect an honorary diploma Sunday when her Class of 2009 graduated from Carmel High...
Latest News
WALLA WALLA — On the day before her graduation from Walla Walla High School, 18-year-old Brittney Woodland spent the afternoon at home. She watched from her front porch as a couple of movers brought a new couch into the living room. “That looks like fun. Can I help?” she said...
SAN MARCOS, Calif. — Grann Pharmaceuticals today announced a historic milestone in the development of transformative therapies for a rare and debilitating genetic disorder known as Rett Syndrome. The company’s very first patient, Eleanor Elnekaveh, has successfully completed the experimental treatment regimen of RTT-1 (Eleanor), an mRNA lipid nanoparticle (LNP) protein replacement...
Bethesda, Md. — Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, announced that Eurostars and Innosuisse have awarded a grant in the aggregate amount of €1.2 million to a consortium led...
John Steinbeck’s epic novel, Grapes of Wrath, captures the pilgrimage of the Joad family from Oklahoma to California and their individual and collective struggles along the journey. Steinbeck could easily write a similar saga titled Grapes of Health for a molecule from grapes that is being targeted for treating rare...
John Steinbeck’s epic novel, Grapes of Wrath, captures the pilgrimage of the Joad family from Oklahoma to California and their individual and collective struggles along the journey. Steinbeck could easily write a similar saga titled Grapes of Health for a molecule from grapes that is being targeted for treating rare...
SOUTH SAN FRANCISCO, Calif. – Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced that the first patient has been enrolled in the company’s Phase 1/2 clinical trial of GPH101, an investigational...
ROCHESTER, Minn. — Mayo Clinic researchers are reporting positive results in early leukemia clinical trials using the chemical epigallocatechin gallate (EGCG), an active ingredient in green tea. The trial determined that patients with chronic lymphocytic leukemia (CLL) can tolerate the chemical fairly well when high doses are administered in capsule...
PHILADELPHIA – According to results of a study published in Cancer Prevention Research, a journal of the American Association for Cancer Research, men with prostate cancer who consumed the active compounds in green tea demonstrated a significant reduction in serum markers predictive of prostate cancer progression. “The investigational agent used...
STAFFORD, Texas — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the expansion of the clinical trial into Europe. The Company’s application...